Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 480 | 83 | 392 |
| Samples | 208 | 47 | 159 |
| Peptides | 176 | 36 | 143 |
Function
FCMR · Fc mu receptor
Fc receptors specifically bind to the Fc region of immunoglobulins (Igs) to mediate the unique functions of each Ig class. FAIM3 encodes an Fc receptor for IgM (see MIM 147020) (Kubagawa et al., 2009 [PubMed 19858324]; Shima et al., 2010 [PubMed 20042454]).[supplied by OMIM, Jul 2010].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 154 amino-acid changes on canonical ENST00000367091 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in FCMR · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in FCMR – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 3/25 12% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 10/612 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Pheochromocytoma and Paraganglioma | 0/0 0% | 1/71 1% |
| Melanoma | 0/210 0% | 25/1899 1% |
| Cervical Carcinoma | 0/35 0% | 5/422 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Neuroendocrine Tumour | 5/154 3% | 1/577 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 12/1592 1% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 9/1390 1% |
| Ovarian Carcinoma | 4/109 4% | 3/998 0% |
| Ewings Sarcoma | 2/63 3% | 0/262 0% |
| Other Solid Cancers | 0/94 0% | 10/1515 1% |
| Bladder Carcinoma | 1/58 2% | 5/956 1% |
| Gastric Carcinoma | 0/74 0% | 10/1809 1% |
| Colorectal Carcinoma | 6/143 4% | 11/3239 0% |
| Osteosarcoma | 0/45 0% | 1/166 1% |
| Head and Neck Carcinoma | 0/85 0% | 7/1574 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 9/2550 0% |
| Glioma | 0/52 0% | 8/2127 0% |
| Hepatocellular Carcinoma | 1/46 2% | 7/2210 0% |
| Breast Carcinoma | 1/144 1% | 10/3264 0% |
| Biliary Tract Carcinoma | 1/54 2% | 2/950 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Neuroblastoma | 4/87 5% | 0/1331 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 1/810 0% |
Mutation Distribution
Where FCMR is mutated · all tissues, split by cell line vs tissue
How many mutations in FCMR were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 480 mutations in FCMR
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|